Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Treatment Strategies for Psoriasis in Chinese Population
ChiCTR2000036186Phase 4Not yet recruiting
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of acitretin, methotrexate and narrowband ultraviolet B in psoriasis (4 arms), sponsored by Shanghai Skin Disease Hospital. Primary endpoint: Psoriasis Area and Severity Index (PASI). Planned start Jan 2021; status: not yet recruiting.
02
Drugs
acitretinmethotrexatenarrowband ultraviolet B
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2000036186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036186.